manufacturers of glp 1 drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists
Description
Another hurdle is scientific
JAMA 2022;327:534-45.ArticlePubMedPMC 129
BMJ 379 , e071380 (2022)
For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred
